Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

A. Lindsay Frazier, MD

  • Institute Physician
  • Professor of Pediatrics, Harvard Medical School
  • Associate Professor of Epidemiology, Harvard T.H. Chan School of Public Health

Appointment Phone

  • 617-632-3270 (Established Pediatric Patients)
  • 888-733-4662 (New Pediatric Patients)


  • 617-632-5710


Treatment Centers


Clinical Interests

Cancer epidemiology, Cancer prevention in children, Germ cell tumors, Global health



Board Certifications

  • Pediatric Hematology/Oncology
  • Pediatrics


  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology


  • Boston Children's Hospital, Pediatrics


  • Children's Hospital Boston, Pediatrics

Medical School

  • Dartmouth Medical School, 1984


Dr. Frazier received her MD from Dartmouth Medical School in 1984, followed by a pediatric residency at Children’s Hospital Boston and a pediatric hematology-oncology fellowship at DFCI, where she joined the faculty in 1990. She received an ScM from Harvard School of Public Health in 1993. In clinical practice, she concentrates on germ cell tumors, while her epidemiologic research primarily focuses on colorectal cancer screening and prevention.


Cancer Prevention in Adolescents, Colorectal Screening, Germ Cell Tumors

Our research focuses on three main areas: (1) adolescent behaviors that predispose to adult malignancy (e.g., diet, tobacco and alcohol consumption, and level of physical activity); (2) prevention policies for both primary and secondary cancer; and (3) treatment of germ cell tumors in pediatric patients. Three cohort studies serve as the basis for this research: Nurses' Health Study I (NHS I), Nurses' Health Study II (NHS II), and the Growing Up Today Study (GUTS). In analyzing tobacco use among the 16,600 children who participate in GUTS, we have focused on identifying factors that predispose children to progress through the stages of tobacco uptake: abstainer, contemplator, experimenter, occasional user, regular user, and addicted user. We found that increased risk of cigarette use was due to excessive weight concerns, willingness to use tobacco promotional items, use of cigars, and low self-esteem. Among women in the NHS I, we have investigated the relation between alcohol use during adolescence, diet during adolescence, and risk of breast cancer. Whereas no effect was demonstrable for alcohol use during adolescence, the null result may reflect only the low level of drinking among this generation of women. However, we found that increased consumption of potatoes, rice, and french fries during adolescence increased risk of breast cancer, as did increased consumption of fish. Refinement of this work is under way via a more extensive adolescent diet questionnaire sent to 60,000 participants of NHS II. We also have completed a cost-effectiveness model of 26 strategies for screening for colorectal cancer, which confirmed that an annual fecal occult blood test with a sigmoidoscopy every 5 years is both effective and cost-effective. Most other strategies recommended recently by a task force of the Agency for Health Care Policy and Research were actually more costly and less effective. The model allows clinicians to examine the tradeoffs between strategies and to tailor recommendations to the patient. In clinical care, Dr. Frazier is the national expert on germ cell tumors in pediatric patients and oversees the care of these patients referred to DFCI. In addition, she is cochair of two national protocols that opened in 1999 for the treatment of low-risk and high-risk pediatric germ cell tumors and chair of the COG Germ Cell subcommittee in COG Rare Tumors.

Physician Video